To verify whether GDF15 activated downstream signaling pathways through ErbB1 activation, we used transwell assays to examine the effect of ErbB1 inhibitor Erlotinib on the migration and invasion of rhGDF15-treated GC cells. This evidence concerns the gene EGFR and gastric cancer.